Product
Emapalumab
Aliases
Gamifant®, NI-0501
6 clinical trials
14 indications
Indication
Graft FailureIndication
Macrophage Activation SyndromeIndication
Hemophagocytic LymphohistiocytosisIndication
Still's diseaseIndication
Systemic Lupus ErythematosusIndication
Systemic Juvenile Idiopathic ArthritisIndication
Adult-onset Still's diseaseIndication
Primary Immune Regulatory DisorderIndication
Autoimmune LymphoproliferativeIndication
Immune System DiseasesIndication
cytopeniaIndication
Aplastic AnemiaIndication
Hypocellular MarrowClinical trial
An Open Label, Single Arm, Multicentre, Proof of Concept, Phase 2 Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After Allogeneic Hematopoietic Stem Cell TransplantationStatus: Terminated, Estimated PCD: 2022-04-21
Clinical trial
A Two-cohort, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, PK and PD, of Emapalumab in Children and Adults With MAS in Still's Disease or With MAS in Systemic Lupus ErythematousStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Phase 2 Study BRIDGING PRE-TRANSPLANT INFLAMMATORY DAMPENING for PRIMARY IMMUNE REGULATORY DISORDERS (BRIDGE Trial)Status: Recruiting, Estimated PCD: 2027-03-01
Clinical trial
A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged CytopeniaStatus: Not yet recruiting, Estimated PCD: 2026-08-22
Clinical trial
Phase 2a/2b Study Emapalumab: A Window of Opportunity in Pediatric Aplastic AnemiaStatus: Recruiting, Estimated PCD: 2029-05-21
Clinical trial
An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess Its Efficacy, Safety, Impact on Quality of Life, and Long-term Outcome in Pediatric Patients With Primary Hemophagocytic LymphohistiocytosisStatus: Completed, Estimated PCD: 2021-08-18